HealthCor Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-310,250
Closed -$41.6M 24
2022
Q3
$41.6M Buy
+310,250
New +$44.5M 5.21% 2
2022
Q2
Sell
-254,160
Closed -$41.2M 59
2022
Q1
$41.2M Buy
254,160
+129,010
+103% +$18.7M 2.75% 14
2021
Q4
$16.9M Buy
+125,150
New +$14.8M 0.92% 34
2021
Q2
Sell
-729,420
Closed -$78.9M 73
2021
Q1
$78.9M Sell
729,420
-124,230
-15% -$13.3M 2.79% 12
2020
Q4
$91.5M Sell
853,650
-465,250
-35% -$44.7M 3.53% 8
2020
Q3
$116M Buy
1,318,900
+1,330
+0.1% +$125K 4.62% 8
2020
Q2
$129M Buy
1,317,570
+853,670
+184% +$75.2M 5.42% 4
2020
Q1
$35.3M Buy
+463,900
New +$39.5M 1.51% 22
2018
Q2
Sell
-574,070
Closed -$54.3M 52
2018
Q1
$54.3M Sell
574,070
-175,340
-23% -$19.3M 1.85% 20
2017
Q4
$72.5M Sell
749,410
-236,910
-24% -$22.3M 2.36% 19
2017
Q3
$87.6M Buy
986,320
+186,890
+23% +$14.2M 2.94% 12
2017
Q2
$58M Buy
+799,430
New +$53.7M 2.09% 18
2016
Q1
Sell
-188,600
Closed -$11.2M 39
2015
Q4
$11.2M Buy
+188,600
New +$10.9M 0.68% 30
2013
Q4
Sell
-1,050,000
Closed -$47M 50
2013
Q3
$47M Buy
+1,050,000
New +$46.5M 2.52% 13

Other funds holding ABBV

HealthCor Management's ABBV Position: Q4 2022 in Review

HealthCor Management sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 310,250 shares — an estimated $41.6M sold.

HealthCor Management first reported a position in ABBV in Q3 2013 and held it in 14 quarters. The position peaked at $129M in Q2 2020. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

  • HealthCor Management reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
  • HealthCor Management sold 310,250 AbbVie shares in Q4 2022, an estimated $41.6M.
  • HealthCor Management first reported a position in AbbVie in Q3 2013 and held it in 14 quarters.
  • HealthCor Management's AbbVie position peaked at $129M in Q2 2020.
  • 3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.